SHANGHAI, China, Sept. 9 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (''China-Biotics,” “the Company”), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it has begun to install equipment for its new manufacturing facility.
The new facility, occupying approximately 789,000 square feet, is located in Qing Pu Industrial Park (the ''Park’’) in Shanghai. Phase 1 of the project will comprise three main buildings and will have a production capacity of 150 metric tons of probiotics per year.
''We are delighted that construction of our new plant is on schedule,’' said Mr. Jinan Song, China-Biotics’ Chairman and Chief Executive Officer. ''We are now installing major manufacturing equipment, and we look forward to commencing production by December 2008.’'
China-Biotics completed construction of the manufacturing building, measuring approximately 130,000 square feet on two levels, at the end of August 2008. A second building will have a research and development center, which will further strengthen the Company’s product development capability. A third building will house a multipurpose office and theater complex, which will be used as an education center to showcase the Company’s products and educate visitors on the probiotics manufacturing process.
About China-Biotics, Inc.
China-Biotics, Inc. (“China-Biotics,” “the Company”), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the ''Shining’’ brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company’s ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Crocker Coulson, President of CCG Investor Relations for China-
Biotics, Inc., +1-646-213-1915 (New York), or crocker.coulson@ccgir.com
Web site: http://www.chn-biotics.com/
http://www.ccgirasia.com/
